Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2018-05-23
Target enrollment:
Participant gender:
Summary
This is a randomized trial to evaluate the clinical benefit of sorafenib 400 mg twice daily
and erlotinib 150 mg once a day versus sorafenib 400 mg twice daily and placebo erlotinib
once daily in subjects with unresectable advanced or metastatic Child-Pugh A HCC. Patients
who are candidates for potentially curative intervention (i.e. surgical resection or local
ablation) are not eligible for this study.